<DOC>
	<DOCNO>NCT00127218</DOCNO>
	<brief_summary>The purpose study investigate add benefit increase high-density lipoprotein ( HDL ) cholesterol serum level achieve lipid lower therapy guide current guideline , old individual cardiovascular disease .</brief_summary>
	<brief_title>High-Density Lipoprotein ( HDL ) Cholesterol Increased Plaque Stabilization Elderly</brief_title>
	<detailed_description>The hypothesis test current standard lipid lower therapy , combine 20 percent great increase serum HDL induce long-acting niacin , reduce plaque size old individual cardiovascular disease . The specific aim test hypothesis : 1. determine effect statin plus placebo vs. statin plus niacin therapy plaque size composition , 2. determine whether alteration inflammatory marker atherosclerosis induced lipid lower therapy parallel alteration plaque architecture composition old patient cardiovascular disease , 3. determine effect intervention incidence cardiovascular cerebrovascular event . The result trial directly applicable develop strategy plaque stabilization elderly suffer severe complication advance cardiovascular atherosclerosis . A total 144 participant age 65 old cardiovascular cerebrovascular disease recruit . Participants randomize receive either statin plus niacin statin plus placebo 18 month . Participants provide prescription fluvastatin 80 mg take daily basis , may continue ongoing cholesterol-lowering drug pravastatin 80 mg daily , simvastatin 20 mg daily , atorvastatin 20 mg daily rosuvastatin 20 mg daily . Ten visit expect , initially every 4 week dose adjustment . Then visit every 6 month ; MRI , Inflammatory Markers test , lab test do baseline visit month 6 , 12 , 18 .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Aged 65 old Documented clinical cardiovascular cerebrovascular disease due atherosclerosis Candidate lipid lower therapy ; contraindication fluvastatin , niacin aspirin therapy Lowdensity lipoprotein ( LDL ) cholesterol 150 mg/dl untreated 125 mg/dl statin monotherapy Willing discontinue present therapy private physician agree enrollment Eligible undergo transesophageal magnetic resonance imaging ( MRI ) ; contraindication GadoliniumDTPA , contrast agent use Willing sign Informed Consent Ineligibility MRI procedure due pacemaker , metal implant , ferromagnetic device Claustrophobia Previously document esophageal disease would preclude transesophageal MRI LDLC great 150 mg/dl lipid lower therapy daily statin therapy require dos great 20 mg atorvastatin , 20 mg simvastatin , 80 mg lovastatin , 80 mg pravastatin , 80 mg extend release fluvastatin , 20 mg rosuvastatin Contraindication allergy statin aspirin Current use know intolerance allergy Niaspan ( longacting niacin ) Allergy intolerance GadoliniumDTPA ( MRI contrast agent ) Liver kidney failure define clinically laboratory data Mental , neurologic social condition prevent understanding rationale , procedure , risk potential benefit associate trial</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>atherosclerotic plaque</keyword>
	<keyword>MRI</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>statin</keyword>
</DOC>